Register by Friday, June 23 to save up to $500
The following questions will be answered:
Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center
Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service. Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials.
The following questions will be addressed:
Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic
Saad S. Kenderian, MD is a senior associate consultant in the Division of Hematology at the Mayo Clinic. He holds the academic rank of Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine. After completing a combined fellowship in hematology and medical oncology, he joined the Division of Hematology at Mayo, received the Mayo Scholar award and joined the Translational Research Program of the University of Pennsylvania as a Mayo Scholar, where he worked in T cell immunotherapy for over two years. He returned to the Mayo Clinic in early 2016. Dr. Kenderian has been honored with numerous awards during his training and career. He is a member of the American Society of Hematology, American Society for Blood and Marrow Transplantation, American Association for Cancer Research. Dr. Kenderian has authored or co-authored more than 25 articles in peer-reviewed journals and he holds several patents in the field of engineered T cell therapy.
The following areas will be discussed:
Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair , in Diabetes, University of Massachusetts Medical School
Dr. Brehm received his Ph.D. from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to model human T cell responses. Dr. Brehm has published over 80 manuscripts and reviews and is supported by funding from the JDRF, NIAID, NIDDK and the Helmsley Charitable Trust.
Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories
Barbara Joyce-Shaikh completed her B.S in with Molecular Biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immunoncology. Her work has contributed several patents as well as medical literature published in journals such as Nature, Immunity, Nature Medicine, and the Journal of Experimental Medicine. She is currently a Project Leader in the Discovery Immunoncology group at Merck Research Laboratories, Palo Alto (Formerly DNAX Research Institute). Her current research utilizes humanized mouse systems and is focused on understanding how tumor stroma and immune cell interactions can be altered with novel immunomodulatory agents in different cancers.